Quantcast

Latest Doxorubicin Stories

2011-05-18 17:16:00

SAN FRANCISCO, May 18, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), being held June 3-7, 2011 in Chicago, Illinois.

2011-05-16 15:23:39

A new discovery in mice by researchers at Wake Forest Baptist Medical Center may one day allow doctors to spare some patients with acute myeloid leukemia (AML) from toxic treatments, while also opening the door for new therapeutic research.

2011-05-04 21:29:32

The ability to use nanoparticles to deliver payloads of cancer-fighting drugs to tumors in the body could herald a fundamental change in chemotherapy treatment.

2011-05-03 00:30:00

SEATTLE, May 3, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced that the Office of New Drugs (the "OND") of the U.S.

2011-04-21 07:00:00

SAN FRANCISCO, April 21, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company's oncology drug candidate, NKTR-102, has been granted orphan drug status for the treatment of women with ovarian cancer by the U.S.

2011-04-20 03:33:00

BARCELONA, April 20, 2011 /PRNewswire/ -- - Advancell has announced the initiation of a clinical phase IIb study of its treatment ATH008 for palmar-plantar erythrodysesthesia syndrome, or hand-foot syndrome, a painful side effect of chemotherapy.

2011-04-02 00:00:28

MM-111 in pre-clinical combinations with lapatinib and endocrine therapies MM-302 in pre-clinical studies explaining its mechanism of action Cambridge, Mass. (Vocus/PRWEB) April 01, 2011 Merrimack Pharmaceuticals, Inc.

2011-03-21 01:30:00

SEATTLE, March 21, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has initiated its randomized pivotal trial of pixantrone for the treatment of relapsed/refractory diffuse large B-cell lymphoma ("DLBCL").

2011-03-16 08:32:00

MONTREAL, March 16 /PRNewswire/ - Soon, drug delivery that precisely targets cancerous cells without exposing the healthy surrounding tissue to the medication's toxic effects will no longer be an oncologist's dream but a medical reality, thanks to the work of Professor Sylvain Martel, Director of the Nanorobotics Laboratory at Polytechnique Montréal. Known for being the world's first researcher to have guided a magnetic sphere through a living artery, Professor Martel is...


Word of the Day
lahar
  • A volcanic mudflow.
The word 'lahar' comes from Javanese.
Related